Filter Results:
(999)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
Show Results For
- All HBS Web
(999)
- People (4)
- News (260)
- Research (614)
- Events (9)
- Multimedia (24)
- Faculty Publications (397)
- June 2021
- Supplement
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)
By: Amitabh Chandra and Spencer Lee-Rey
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (B)." Harvard Business School Supplement 621-111, June 2021.
- July 2010
- Teaching Note
Metabical: Positioning and Communications Strategy for a New Weight Loss Drug (Brief Case)
By: John A. Quelch and Heather Beckham
Teaching note to case #4240. View Details
- Article
Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting
By: J. H. Gurwitz, T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson and D. W. Bates
Gurwitz, J. H., T. S. Field, J. Avorn, D. McCormick, S. Jain, M. Eckler, M. Benser, A. Edmondson, and D. W. Bates. "Incidence and Preventability of Adverse Drug Events in the Nursing Home Setting." American Journal of Medicine 109, no. 2 (2000): 87–94.
- 12 Sep 2019
- Podcast
We Need a Miracle: How Drug R&D Needs to Change to Cure Disease
Healthcare digitization is booming and data-driven innovations are disrupting drug discovery. But we must learn how to use these emerging technologies better so that we can ask more sophisticated questions, and come up with deeper insights into biology and the... View Details
- Summer 2021
- Article
The Cost and Evolution of Quality at Cipla Ltd, 1935–2016
By: Muhammad H. Zaman and Tarun Khanna
This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details
Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India
Zaman, Muhammad H., and Tarun Khanna. "The Cost and Evolution of Quality at Cipla Ltd, 1935–2016." Business History Review 95, no. 2 (Summer 2021): 249–274.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001): 32–59.
- June 2021
- Case
Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)
By: Amitabh Chandra and Spencer Lee-Rey
Chandra, Amitabh, and Spencer Lee-Rey. "Who Lives & Who Dies: Expanded Access for Experimental Drugs at Chimerix (A)." Harvard Business School Case 621-110, June 2021.
- 2022
- Working Paper
Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development
By: Henrik Bresman and Amy C. Edmondson
Breakthrough performance in teams requires pooling diverse perspectives and expertise. To realize the potential of diversity, communicating and translating across differences is essential. However, left to their own devices, diverse teams tend to underperform, in part... View Details
Keywords: Teams; Psychological Safety; Groups and Teams; Diversity; Interpersonal Communication; Performance
Bresman, Henrik, and Amy C. Edmondson. "Exploring the Relationship between Team Diversity, Psychological Safety and Team Performance: Evidence from Pharmaceutical Drug Development." Harvard Business School Working Paper, No. 22-055, February 2022.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca Henderson and Iain Cockburn
Henderson, Rebecca, and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001).
- December 2000
- Article
Risk versus Risk: Tragic Choices in Drug Regulation in the United States and Germany
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Risk versus Risk: Tragic Choices in Drug Regulation in the United States and Germany." Science as Culture 9, no. 4 (December 2000): 505–534.
- Article
Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-Five Years of Drug Lag Debate." Pharmacy in History 45, no. 1 (2003): 3–17.
- October 2021 (Revised October 2022)
- Case
The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details
Keywords: Opioids; Drug; Investors; Shareholder Activism; Investment Activism; Executive Compensation; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Legal Liability; Distribution Industry; Health Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen." Harvard Business School Case 122-014, October 2021. (Revised October 2022.)
- February 2024
- Case
Civica Rx: A Not-for-Profit Founded to Address Market Failures in the Generic Drug Industry
By: Leemore S. Dafny
Dafny, Leemore S. "Civica Rx: A Not-for-Profit Founded to Address Market Failures in the Generic Drug Industry." Harvard Business School Case 324-057, February 2024.
- April 2010
- Teaching Note
Metabical: Pricing, Packaging, and Demand Forecasting Recommendations for a New Weight Loss Drug (Brief Case)
By: John A. Quelch and Heather Beckham
Teaching Note to 4183 View Details
- October 2023
- Article
Clinician Response to Patient Medication Prices Displayed in the Electronic Health Record
By: Anna D Sinaiko, Caroline E Sloan, Mark J Soto, Olivia Zhao, Chen-Tan Lin and Foster R Goss
Keywords: Prescription Drugs; Electronic Health Records; Physicians; Prescription Drug Costs; Health Care and Treatment; Price; Health Industry
Sinaiko, Anna D., Caroline E Sloan, Mark J Soto, Olivia Zhao, Chen-Tan Lin, and Foster R Goss. "Clinician Response to Patient Medication Prices Displayed in the Electronic Health Record." JAMA Internal Medicine 183, no. 10 (October 2023): 1172–1175.
- Article
Strategic Assets, Interdependence and Technological Change: An Empirical Investigation of Complementarity in Pharmaceutical Drug Discovery
By: S. Thomke and W. Kuemmerle
Keywords: Strategy; Assets; Information Technology; Change; Information; Health; Pharmaceutical Industry
Thomke, S., and W. Kuemmerle. "Strategic Assets, Interdependence and Technological Change: An Empirical Investigation of Complementarity in Pharmaceutical Drug Discovery." Academy of Management Proceedings and Membership Directory (2000).
- January 2020
- Case
Celata Bioinnovations
By: John R. Wells and Benjamin Weinstock
In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details
Keywords: Drug Development; Drug Discovery; Drug Trials; Pharmaceutical Companies; Pharmaceutical Company; Pharmaceuticals; Therapeutics; Biologics; Biotech; Biotechnology; Biopharmacy Company; Biochemistry; Technology Commercialization; Technology Companies; Drug Testing; Startup; Start-up; Startups; Start-ups; Startup Financing; Strategic Decision Making; Strategic Decisions; Strategic Evolution; FDA; Food And Drug Administration; Clinical Trials; Disease Management; Market Attractiveness; Market Entry; Market Opportunities; Health Disorders; Technological Innovation; Information Technology; Commercialization; Business Startups; Finance; Decision Making; Strategy; Market Entry and Exit; Opportunities; Pharmaceutical Industry; Biotechnology Industry
Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.
- Article
Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry
By: Leemore S. Dafny, Christopher Ody and Matt Schmitt
The analogy between value-based purchasing in pharmaceuticals and the new frontier of alternative payment models for health care providers is relatively straightforward. Insurers are increasingly demanding steep discounts from providers in exchange for inclusion in... View Details
Keywords: Drug Copayment Coupons; Prescription Drug Policy; Health Care and Treatment; Insurance; Cost; Policy; Pharmaceutical Industry
Dafny, Leemore S., Christopher Ody, and Matt Schmitt. "Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry." New England Journal of Medicine 375, no. 21 (November 24, 2016): 2013–2015.